Millennium Management LLC Purchases 77,912 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Millennium Management LLC grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 205.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,918 shares of the company's stock after acquiring an additional 77,912 shares during the quarter. Millennium Management LLC owned about 0.18% of Kymera Therapeutics worth $4,663,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in shares of Kymera Therapeutics by 14.0% during the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after acquiring an additional 53,658 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after purchasing an additional 20,346 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Kymera Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after purchasing an additional 2,011 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Kymera Therapeutics by 174.2% in the 4th quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock worth $801,000 after purchasing an additional 12,643 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Kymera Therapeutics by 51.8% in the 4th quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after purchasing an additional 7,487 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KYMR. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective on the stock. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research note on Monday. Citigroup initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $55.69.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $13.49 on Monday, hitting $43.13. 6,308,996 shares of the company traded hands, compared to its average volume of 591,186. The stock has a market capitalization of $2.81 billion, a P/E ratio of -18.43 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The business has a 50-day simple moving average of $28.84 and a 200 day simple moving average of $35.59.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company's revenue for the quarter was up 114.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.69) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.